Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Argenx Se ADR (NQ: ARGX )

382.10 +3.38 (+0.89%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Argenx Se ADR

< Previous 1 2 3 Next >
Analyst Ratings for argenx
 
Via Benzinga
AT&T To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Tuesday
Keybanc boosted Five Below, Inc. (NASDAQ: FIVE) price target from $188 to $200. Keybanc analyst Bradley Thomas maintained an Overweight rating on the stock. Five Below shares fell 1.6% to $183.92 in... 
Via Benzinga
Alphabet To $115? Here Are 10 Other Price Target Changes For Thursday
Stifel raised argenx SE (NASDAQ: ARGX) price target from $471 to $478. Stifel analyst Alex Thompson maintained a Buy rating on the stock. argenx shares rose 1.1% to $387.07 in pre-market trading. 
Via Benzinga
Analyst Ratings for argenx
 
Via Benzinga
Expert Ratings for argenx
 
Via Benzinga
Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position
 
Via Benzinga
7 Analysts Have This to Say About argenx
argenx (NASDAQ:ARGX) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Argenx's Drug Scores European Approval For Muscular Fatigue Disorder
 
Via Benzinga
Argenx's Vyvgart To 'Achieve Blockbuster Status,' This Analyst Says With 6% Price Target Hike
 
Via Benzinga
argenx: Q2 Earnings Insights
  argenx (NASDAQ:ARGX) reported its Q2 earnings results on Thursday, July 28, 2022 at 01:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's session, 108 stocks hit new 52-week highs. 
Via Benzinga
Argenx's Flagship Neuromuscular Treatment For Subcutaneous Injection Goes Under Priority FDA Review
 
Via Benzinga
McDonald's To Rally Over 13%? Here Are 5 Other Price Target Changes For Friday
Wedbush raised McDonald's Corporation (NYSE: MCD) price target from $265 to $300. Wedbush analyst Nick Setyan maintained the stock with an Outperform rating. McDonald's shares rose 3.3% to close at... 
Via Benzinga
Recap: argenx Q3 Earnings
argenx (NASDAQ:ARGX) reported its Q3 earnings results on Thursday, October 27, 2022 at 01:00 AM. Here's what investors need to know about the announcement. Earnings argenx missed estimated earnings by... 
Via Benzinga
Immunovant's New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say
 
Via Benzinga
Argenx Seeks FDA Nod For Its Flagship Neuromuscular Treatment Formulated For Subcutaneous Injection
 
Via Benzinga
Recap: argenx Q2 Earnings
  argenx (NASDAQ:ARGX) reported its Q2 earnings results on Thursday, July 28, 2022 at 01:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
What 5 Analyst Ratings Have To Say About argenx
Analysts have provided the following ratings for argenx (NASDAQ:ARGX) within the last quarter: 
Via Benzinga
SVB Sees Strategic Value In This Stock As M&A Target In Autoimmune Space
 
Via Benzinga
Argenx's Vyvgart Meets Primary Goal In Late-Stage Bleeding Disorder Study
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022
Upgrades 
Via Benzinga
Recap: argenx Q1 Earnings
argenx (NASDAQ:ARGX) reported its Q1 earnings results on Thursday, May 5, 2022 at 01:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
Argenx Gets European Marketing Authorization For Neuromuscular Disorder Candidate
The European Commission (EC) has granted marketing authorization for Argenx’s (NASDAQ: ARGX) lead asset VYVGART (efgartigimod alfa-fcab) as an add-on to standard therapy for the treatment of adult... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 29, 2022
  
Via Benzinga
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Piper Sandler Maintains Overweight Rating for argenx: Here's What You Need To Know
Piper Sandler has decided to maintain its Overweight rating of argenx (NASDAQ:ARGX) and raise its price target from $415.00 to $425.00. Shares of argenx are trading up 1.84% over the last 24 hours, at... 
Via Benzinga
Golden Cross Appears Before argenx Investors
If history is any guide, there may be good fortune ahead for shares of argenx (NASDAQ:ARGX). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the... 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2022
Upgrades 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.